Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
This randomized phase III trial is studying giving tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage III or stage IV breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen* or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving hormone therapy is more effective with or without bevacizumab in treating advanced breast cancer
I. To compare the progression-free survival of women with estrogen- and/or progesterone-receptor-positive stage IIIB-IV breast cancer treated with letrozole with vs without bevacizumab as first-line treatment.
I. To compare the proportion of patients receiving letrozole with or without bevacizumab who remain progression-free at 6 and 12 months.
II. To compare the incidence of objective response (complete response [CR] + partial response [PR]) in patients receiving letrozole with or without bevacizumab, as determined by RECIST criteria, excluding patients with non-measurable disease.
III. To compare the incidence of clinical benefit (CR + PR + stable disease >= 6 months) in patients receiving letrozole with or without bevacizumab.
IV. To compare the duration of objective response in patients receiving letrozole with or without bevacizumab.
V. To compare the time to treatment failure, defined as the interval from randomization until progression, toxicity, withdrawn consent, or going onto non protocol therapy, in patients receiving letrozole with or without bevacizumab.
VI. To compare the overall survival of patients receiving letrozole with or without bevacizumab, including the probability of survival until 36 months.
V. To compare toxicity levels of bevacizumab in both the letrozole-treated patients and in the tamoxifen-treated* patients.
VI. To compare progression-free survival and overall survival of all patients receiving endocrine therapy with and without bevacizumab (by combining both letrozole and tamoxifen* patient subgroups). NOTE: *As of 5/15/2011, patients only receive letrozole.
OUTLINE: This is a multicenter study. Patients are stratified according to planned endocrine therapy* (letrozole vs tamoxifen*), disease measurability (no vs yes), and disease-free interval from initial diagnosis to first progression (≤ 24 months vs > 24 months). Patients are randomized to 1 of 2 treatment arms.
NOTE: The placebo-controlled portion of the study was canceled on 5-15-10
ARM I: Patients receive oral endocrine therapy* (tamoxifen citrate or letrozole) once daily on days 1-21 and bevacizumab IV on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive oral endocrine therapy* (tamoxifen citrate or letrozole) once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up every 6 months for the first 2 years and then annually for up to 3 years.
NOTE: As of 5/15/2011, patients only receive letrozole.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Recurrent Breast Cancer
tamoxifen citrate, letrozole, bevacizumab
Active, not recruiting
National Cancer Institute (NCI)
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00601900
- Information obtained from ClinicalTrials.gov on April 16, 2013
Medical and Biotech [MESH] Definitions
Inflammatory Breast Neoplasms
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Tumors or cancer of the human BREAST.
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
RATIONALE: Estrogen can cause the growth of breast cancer cells. Aromatase inhibitors, such as letrozole, anastrozole, and exemestane, may fight breast cancer by lowering the amount of est...
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using t...
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or...
The purpose of this research project is to study the effect of a research (investigational) drug, MK-0752 combined with either tamoxifen or letrozole on breast cancer cells. Tamoxifen and...
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells. Studyin...
PURPOSE Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free surviv...
To evaluate changes in serum lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and lipoprotein(a) [Lp(a)]), in postmenopausal women receiving letrozole after tamoxifen th...
OBJECTIVE: To assess the effectiveness of tamoxifen administration with letrozole in the context of intrauterine insemination (IUI) cycles. MATERIALS AND METHODS: This prospective double-blinded study...
Abstract Background: The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (...
Abstract Background: Third-generation aromatase-inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced-breast-cancer compared with tamoxifen. For HR+, HER2+ MBC, combin...